Generics
Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen
April 04, 2018Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.
Teva rebrands in North America amid global restructuring
March 02, 2018The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.
Five things for pharma marketers to know: Tuesday, January 23, 2018
January 23, 2018FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW
Five things for pharma marketers to know: Friday, January 19, 2018
January 19, 2018Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit
Five things for pharma marketers to know: Tuesday, January 9, 2018
January 09, 2018Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018
Five things for pharma marketers to know: Thursday, January 4, 2018
January 04, 2018Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy
Five things for pharma marketers to know: Tuesday, December 26, 2017
December 26, 2017Roche to buy Ignyta for $1.7 billion; FDA OKs Valeant eye drop for OTC sale; Kmart settles prescription drug fraud allegations
Five things for pharma marketers to know: Thursday, December 14, 2017
December 14, 2017Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business
Five things for pharma marketers to know: Friday, December 15, 2017
December 14, 2017FDA approves first topical skin growth treatment; Teva to cut 14,000 jobs; Novartis Oncology CEO resigns
Five things for pharma marketers to know: Wednesday, December 13, 2017
December 13, 2017Teva diminishes debt with job cuts and sale; FDA to study whether consumers can detect misleading ads; AbbVie, Roche present positive Phase-III data at ASH
Five things for pharma marketers to know: Monday, December 11, 2017
December 11, 2017Pfizer's Viagra generic to sell for half the price; GSK seeks oncology deals; Ionis' experimental Huntington's drug tackles toxic protein for the first time
Five things for pharma marketers to know: Monday, November 27, 2017
November 27, 2017Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up
Five things for pharma marketers to know: Thursday, November 2, 2017
November 02, 2017Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III
Five things for pharma marketers to know: Wednesday, August 9, 2017
August 09, 2017The FDA on pace for record generic drug approvals; CVS Health CEO doubts Amazon's entrance to pharmacy market; Sanofi to develop cancer immunotherapy
Five things for pharma marketers to know: Thursday, July 27, 2017
July 27, 2017Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug
Five things for pharma marketers to know: Monday, July 24, 2017
July 24, 2017Samsung Bioepis launches Remicade biosimilar; WHO encourages uses of generic version of Sovaldi; nearly 20 million people with HIV on treatment
Five things for pharma marketers to know: Thursday, June 29, 2017
June 29, 2017Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition
Five things for pharma marketers to know: Thursday, June 22, 2017
June 22, 2017The FDA plans public meeting to encourage generic competition; Mylan reportedly offered rebates to six Medicaid programs; Republicans to present draft bill for Obamacare replacement
Five things for pharma marketers to know: Thursday, June 15, 2017
June 15, 2017Google invests in European biotechs; hospitals that restrict sales-rep visits more likely to prescribe cheaper generics; AI could help doctors with new research
Five things for pharma marketers to know: Monday, June 12, 2017
June 12, 2017Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative
Five things for pharma marketers to know: Friday, June 9, 2017
June 09, 2017The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision
Five things for pharma marketers to know: Friday, April 28, 2017
April 28, 2017Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective
Five things for pharma marketers to know: Wednesday, February 15, 2017
February 15, 2017Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
GSK prepares for Advair competition
February 08, 2017If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.
Five things for pharma marketers to know: Tuesday, February 7, 2017
February 07, 2017Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
Five things for pharma marketers to know: Wednesday, January 18, 2017
January 18, 2017Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem
Five things for pharma marketers to know: Tuesday, February 2, 2016
February 02, 2016Gleevec generics hit shelves; four OxyContin patents are invalidated; Sanofi axes 600 positions
Five things for pharma marketers to know: Thursday, September 3, 2015
September 03, 2015Novartis launches Zarxio, the first US biosimilar; UCB sells its generic business; one-third of children with ADHD are diagnosed before they turn six
Five things for pharma marketers to know: Monday, May 18
May 18, 2015Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition
